

19/10/2015

Dear Editor,

We are grateful for the reviewers' comments. We have carefully inspected the suggestions. We have not performed a CrossCheck because this review is a novel study and was written in Turkish originally, then it was translated to English by a native speaker. Numerous corrections have been performed due according to reviewers' comments. These are;

-postcodes in page 1.

-detailed correspondence address

-audio core tip

-reference numbers in square brackets and superscript

-reference section was revised. Many reference format errors were corrected and PMID/DOI numbers were added if available.

*Reviewer: Sir, That is an interesting article on different forms of prophylaxis of Pneumocystis jiroveci infection in transplant recipients. My suggestion is to present not only the duration of classical prophylaxis but also some hints on the dosage in a core prophylaxis. with Trimethoprim sulfametaxazol. Data on pentamidine prophylaxis are interesting but remain still a matter of debate. For that reason my suggestion will be to change the title of the article Pneumocystis jiroveci Prophylaxis in Heart Transplant Recipients -focus on pentamidine. Additionally please correct multiple omission of spaces between words - it will be important for good reading. Best regards*

Thank you for your fast and detailed advises. Core prophylaxis protocol with Trimethoprim sulfametaxazol was written in "AGENTS USED FOR PROPHYLAXIS" as well. The data on pentamidine is extremely rare. There are only a few numbers of reports on this issue and there is not a consensus about its usage in heart transplant patients; so that was our motivation to search what were other clinicians doing on prophylaxis of P.jiroveci in different subspecialties. Finally the title was transformed to "Pentamidine in Pneumocystis jiroveci Prophylaxis in Heart Transplant Recipients" due your suggestion.

Kindest regards,

Dr. Adem Ilkay Diken